Abstract
Diabetic macular edema is one of the leading causes of visual loss in first world countries and the first cause in diabetic retinopathy. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. Nevertheless, progressive visual loss is found in the 26% of patients with diabetic macular edema treated with photocoagulation. The failure of laser treatment and the destructive nature of the therapy has forced researchers to pursue new alternatives including vitrectomy with or without internal limiting membrane peels, the use of proteinkinase C inhibitors, intravitreal injections of antibodies that inhibit the vascular endothelial growth factor, somatostatin analog, or the intravitreal injection with corticosteroids. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Publications evaluating the safety and efficacy of intravitreal injection of triamcinolone in the treatment of diabetic macular edema show varying outcomes with respect to the increases of visual acuity and decreases in foveal thickness. Despite this, intravitreal triamcinolone is a treatment that has evolved quickly and is considered increasingly useful.
Keywords: Diabetic macular edema, Intravitreal triamcinolone
Current Diabetes Reviews
Title: Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema
Volume: 2 Issue: 1
Author(s): Francisco Gomez-Ulla, Joaquin Marticorena, D. V. Alfaro III, Maribel Fernandez, Elizabeth R. Mendez and Michelle Rothen
Affiliation:
Keywords: Diabetic macular edema, Intravitreal triamcinolone
Abstract: Diabetic macular edema is one of the leading causes of visual loss in first world countries and the first cause in diabetic retinopathy. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. Nevertheless, progressive visual loss is found in the 26% of patients with diabetic macular edema treated with photocoagulation. The failure of laser treatment and the destructive nature of the therapy has forced researchers to pursue new alternatives including vitrectomy with or without internal limiting membrane peels, the use of proteinkinase C inhibitors, intravitreal injections of antibodies that inhibit the vascular endothelial growth factor, somatostatin analog, or the intravitreal injection with corticosteroids. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Publications evaluating the safety and efficacy of intravitreal injection of triamcinolone in the treatment of diabetic macular edema show varying outcomes with respect to the increases of visual acuity and decreases in foveal thickness. Despite this, intravitreal triamcinolone is a treatment that has evolved quickly and is considered increasingly useful.
Export Options
About this article
Cite this article as:
Gomez-Ulla Francisco, Marticorena Joaquin, Alfaro III V. D., Fernandez Maribel, Mendez R. Elizabeth and Rothen Michelle, Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema, Current Diabetes Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339906775473572
DOI https://dx.doi.org/10.2174/157339906775473572 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture Cellular and Humoral Responses following Minimally Invasive Surgery: Role of Reactive Oxygen Species
Current Metabolomics Effects of Natural Products on Contact Dermatitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Formulation and Standardization of Anti-acne Herbal Foaming Face Wash using <i>Curcuma longa</i> along with <i>Aloe vera, Rosa centifolia</i>, and <i>Cit - rus sinensis</i>
Drug Delivery Letters Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research Exploring the Mechanism of Lingzhu San in Treating Febrile Seizures by Using Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Molecular and Cellular Mechanisms in the Pathophysiology of Severe Head Injury
Current Pharmaceutical Design Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice
Current Alzheimer Research Aquaporins and Glia
Current Neuropharmacology Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease
Current Enzyme Inhibition Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry